3rd Quarter - Report

1DAY SOONER ACTION PROJECT INC. for 1DAY SOONER ACTION PROJECT INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 18, 2026 $40,000 Replaced
3rd Quarter - Amendment Oct 18, 2026 $40,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Clinical trial modernization legislation to make clinical trials faster, cheaper, and more efficient, including redlines on and support for Rep. Auchinclosss clinical trial bill, a supporting coalition letter, and introduction of a Senate companion (Sen. Hickenlooper); S. 4440, the Clinical Trial Modernization Act (Sen. Scott), including participant compensation provisions. Inclusion of pregnant individuals in clinical trials, including H.R. 8651, the Advancing Safe Medications for Moms and Babies Act of 2026 (Rep. Castor, Sen. Hickenlooper). FDA Sentinel system and real-world evidence provisions for potential health data legislation (Sen. Young), including an expert discussion with the office. Suggested questions to Senate staff for a hearing with Heidi Overton.

LobbyistCovered position, as disclosed
KATHRYN TAYLOR LIVELLI New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 8651 (119th), S. 4440 (119th)

Medical/Disease Research/Clinical Labs MED

S. 2333, Pandemic and All-Hazards Preparedness and Response Act (Hickenlooper - Budd Amendment to establish an emerging pathogen preparedness program through the FDA); FY25 & FY26 appropriations bills and NDAA (and report language) to ensure adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness. Discussions with House and Senate offices about potential new legislation related to how the government encourages innovation in health care and other industries. Assistance with pursuing a letter of support from the Senate to the White House re: recent malaria vaccine developments; other interactions with the WH, HHS, and DoD to promote prompt distribution of malaria vaccines To support the FDA - DoD relationship to prioritize the development of safe and effective medical products that could save military personnel lives

LobbyistCovered position, as disclosed
KATHRYN TAYLOR LIVELLI —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Defense, Dept of (DOD)

Bills named: S. 2333 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.